Context Therapeutics Inc. (CNTX) — Financial statements
Income statement, balance sheet, and cash flow for Context Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 32↑40.3% | 23↑27.7% | 18↑150.8% | 7↑86.4% | 4 | |
| General & Administrative Expenses | 8↑8.6% | 7↓0.9% | 7↓6.4% | 8↑114.4% | 4 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 8↑8.6% | 7↓0.9% | 7↓6.4% | 8↑114.4% | 4 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.50↓83.8% | 3 | |
| Operating Expenses | 40↑32.7% | 30↑19.3% | 25↑63.0% | 15↑46.1% | 11 | |
| Total Costs & Expenses | 40↑32.7% | 30↑19.3% | 25↑63.0% | 15↑46.1% | 11 | |
| Operating Results | ||||||
| Operating Income | -40↓32.7% | -30↓19.3% | -25↓63.0% | -15↓46.1% | -11 | |
| Depreciation & Amortization | 0.02↑49.4% | 0.01↓9.7% | 0.01↑30.0% | 0.01 | 0.00 | |
| EBITDA | -40↓32.7% | -30↓19.4% | -25↓68.5% | -15↓43.1% | -10 | |
| EBIT | -40↓32.7% | -30↓19.3% | -25↓68.5% | -15↓43.2% | -10 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑5.6% | 3↑174.9% | 1 | 0.00↑100.0% | -0.06 | |
| Interest Income | 3↑5.6% | 3↑174.9% | 1↑112.7% | 0.55↑851811.6% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.55↑751.9% | 0.06 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -0.50↓275.4% | -0.13 | |
| Other Income / Expenses | 4↑11.9% | 3↑188.6% | 1↑103.3% | 0.55↑690.8% | 0.07 | |
| Income Before Tax | -36↓35.2% | -27↓11.5% | -24↓61.5% | -15↓41.9% | -10 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -36↓35.2% | -27↓11.5% | -24↓61.5% | -15↓41.9% | -10 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -36↓35.2% | -27↓11.5% | -24↓61.5% | -15↓41.9% | -10 | |
| Bottom-Line Net Income | -36↓35.2% | -27↓11.5% | -24↓61.5% | -15↓41.9% | -10 | |
| EPS (Basic) | -0.38↑17.4% | -0.46↑69.3% | -1.50↓61.3% | -0.93↑74.8% | -3.69 | |
| EPS (Diluted) | -0.38↑17.4% | -0.46↑69.3% | -1.50↓61.3% | -0.93↑74.8% | -3.69 | |
| Weighted Average Shares | 95↑62.9% | 58↑265.9% | 16↑0.0% | 16↑463.4% | 3 | |
| Weighted Average Diluted Shares | 95↑62.9% | 58↑265.9% | 16↑0.0% | 16↑463.4% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.